Health insurance has been the focus of national debate for some time whether the theme of that discussion is price transparency, out-of-network physicians, coverage for pre-existing conditions, Medicaid expansion, and other areas. The upcoming INVEST Digital Health virtual conference September 21-25 will offer a spotlight for this debate to continue.
At MedCity INVEST Digital Health virtual, you’ll hear from leading physician executives, payers, active investors and the most promising digital health startups aiming to solve some of healthcare’s greatest challenges. Click here to see agenda.
Register today using the code MCN100 to get a $100 discount.
The debate will include an entrepreneur, Shawn Wagoner, Co-founder and Chief Revenue Officer, Bind Benefits, who will argue that consumers are ready to be active healthcare consumers, and better insurance design — one that illuminates treatment options with clear prices so consumers know the cost upfront and can make better decisions in advance of care — is the way to get there. Venture capitalist Michael Yang, Managing Partner, OMERS Ventures, will argue that the world of insurance is indeed so complicated that no amount of improved design will do and that consumers need advocates to make prudent decisions that ultimately lower costs overall and for them. Alyssa Jaffee, Vice President, 7Wire Ventures, will serve as the moderator.
The conference, in partnership with healthcare industry association Medical Alley, will also include conversations spanning behavioral health and how hospitals are addressing the pandemic. Digital health startups addressing chronic disease management, Home Health, Employee Benefits and Tech to Improve Payer/Provider Efficiency will also pitch their solutions to panels of investor judges.
Use the code MCN100 to get a $100 discount when you register through this link.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Picture: Getty Images, Dmitrii_Guzhanin
